Compare · CVRX vs SYK
CVRX vs SYK
Side-by-side comparison of CVRx Inc. (CVRX) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVRX and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $129.09B, about 996.9x CVRX ($129.5M).
- Over the past year, CVRX is down 41.8% and SYK is down 16.0% - SYK leads by 25.9 points.
- SYK has been more active in the news (2 items in the past 4 weeks vs 1 for CVRX).
- SYK has more recent analyst coverage (25 ratings vs 13 for CVRX).
- Company
- CVRx Inc.
- Stryker Corporation
- Price
- $4.87+1.88%
- $336.70+1.92%
- Market cap
- $129.5M
- $129.09B
- 1M return
- -7.50%
- +6.50%
- 1Y return
- -41.82%
- -15.96%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 2
- Recent ratings
- 13
- 25
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest CVRX
- CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026
- CVRx Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- CVRx Announces Chief Financial Officer Transition
- Director Nielsen Kirk G. was granted 8,720 shares (SEC Form 4)
- Director Jain Mudit K. was granted 8,720 shares, increasing direct ownership by 154% to 14,370 units (SEC Form 4)
- Director Slattery Joseph P was granted 8,720 shares, increasing direct ownership by 28% to 39,365 units (SEC Form 4)
- Director Hill, Mitch C. was granted 8,720 shares (SEC Form 4)
- Director Ballinger Kevin J. was granted 8,720 shares (SEC Form 4)
- Director Shadan Martha was granted 8,720 shares (SEC Form 4)
- Director Dale Michael D was granted 29,005 shares (SEC Form 4)
Latest SYK
- Stryker expands Mako robotics portfolio with full market release of Mako RPS
- BMO Capital Markets initiated coverage on Stryker with a new price target
- Stryker to announce second quarter 2026 financial results
- Stryker Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Stryker partners with professional golfer Shane Lowry to spotlight the caregiver journey in joint replacement
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)